Covered recipient · General Payments record
REGAN F MILLER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2023
$378.35
- Reported across 23 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $268.37 | 17 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $166.40 | 12 |
| MDD US Operations, LLC | $24.55 | 1 |
| TG THERAPEUTICS, INC. | $22.79 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $21.25 | 1 |
| Otsuka America Pharmaceutical, Inc. | $19.10 | 1 |
| Horizon Pharma plc | $14.28 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.98 | 02/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920485 | CMS |
| ABBVIE INC. | $27.78 | 03/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920487 | CMS |
| ABBVIE INC. | $12.67 | 03/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920489 | CMS |
| ABBVIE INC. | $3.72 | 03/31/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920491 | CMS |
| ABBVIE INC. | $15.53 | 04/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920493 | CMS |
| ABBVIE INC. | $14.36 | 05/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920495 | CMS |
| ABBVIE INC. | $12.50 | 06/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920497 | CMS |
| ABBVIE INC. | $27.50 | 09/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920499 | CMS |
| ABBVIE INC. | $4.23 | 10/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920501 | CMS |
| ABBVIE INC. | $24.06 | 11/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920503 | CMS |
| ABBVIE INC. | $1.31 | 11/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920505 | CMS |
| ABBVIE INC. | $4.76 | 11/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997920507 | CMS |
| Horizon Therapeutics plc | $14.28 | 08/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 987047063 | CMS |
| MDD US Operations, LLC | $24.55 | 04/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1052887089 | CMS |
| Novartis Pharmaceuticals Corporation | $21.25 | 02/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 992923063 | CMS |
| Otsuka America Pharmaceutical, Inc. | $19.10 | 10/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1014587571 | CMS |
| TG Therapeutics, Inc. | $22.79 | 02/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1051475303 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.